A Brief History of Peptide Synthesis

The fact that you can order tirzepatide as a reference standard for under $200 per vial is the end result of about 120 years of organic chemistry. The history is short by chemistry standards and worth knowing.

1901 — The Fischer dipeptide

Emil Fischer synthesized glycyl-glycine — the first dipeptide produced by deliberate chemical bond formation between two amino acids — in 1901. The technique was solution-phase coupling: each step required isolation, purification, and characterization. Synthesizing anything longer than a few amino acids was impractical.

1953 — du Vigneaud’s oxytocin

Vincent du Vigneaud published the synthesis of oxytocin in 1953 — a 9-amino-acid peptide. This earned him the Nobel Prize in Chemistry in 1955. The synthesis took years of work using solution-phase methods.

The achievement was the demonstration that biologically active peptides could be made deliberately. The cost — in labor — was extreme.

1963 — Merrifield and solid-phase synthesis

Bruce Merrifield published the solid-phase peptide synthesis (SPPS) approach in 1963. The fundamental insight: anchor the C-terminal amino acid to an insoluble polymer bead, then add each subsequent amino acid in solution, washing away byproducts and excess reagents after every coupling. No isolation, no purification, between steps.

This collapsed peptide synthesis from a multi-year project per peptide to a multi-day project per peptide. Merrifield won the 1984 Nobel Prize.

1970s — Protecting group chemistry

SPPS required reliable protecting groups: chemical modifications that block reactive side chains during coupling and can be removed cleanly at the end of synthesis. The Fmoc (9-fluorenylmethoxycarbonyl) and Boc (tert-butyloxycarbonyl) strategies emerged in this period. Both are still in routine use, with Fmoc the more common modern default.

1980s — Automated synthesizers

By the late 1980s, commercially available automated peptide synthesizers performed the SPPS cycle programmatically — coupling, washing, deprotecting, repeating. The time-per-amino-acid dropped from hours to minutes.

1990s — Manufacturing scale

By the 1990s, contract manufacturing organizations were producing peptides at multi-gram and kilogram scale using SPPS for peptides up to roughly 50 amino acids. Larger sequences required chemical ligation strategies (Native Chemical Ligation, NCL) or recombinant expression.

2000s-2020s — The modern reference market

The combination of automated SPPS, reliable analytical methods (HPLC, mass spec), and global manufacturing competition has made research peptides commodity-accessible. A 30-amino-acid reference peptide that would have been a doctoral thesis in 1963 is now an item in a catalog.

What this means for procurement

The economics of peptide synthesis explain a lot of what you see in the research-peptide market:

• Short peptides (under 10 amino acids) are cheap to make. GHK, BPC-157, oxytocin reference standards are inexpensive.
• Medium peptides (10-30 amino acids) are routine. Most research peptides fall here.
• Long peptides (30-50 amino acids) are still SPPS-accessible but more expensive. Tirzepatide (39 AA) sits here.
• Very long peptides (50+ amino acids) typically require chemical ligation or recombinant expression. Manufacturing economics shift.

What it doesn’t change

Synthesis quality varies dramatically across manufacturers — even for the same target peptide. Reliable synthesis at scale requires substantial process control. The HPLC purity figure on the COA is your window into how well the manufacturer’s process is running.

The history made the molecules accessible. Quality control is what separates one supplier from another.